• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Details
Files
DOI
10.7892/boris.123259
Publisher DOI
10.1038/s41409-018-0340-0
PubMed ID
30531954
Abstract
Ocular graft-versus-host disease (GVHD) occurs in more than half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity, which affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed in this review. Ocular GVHD has at least three biological processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Preclinical models have found several novel pathogenic mechanisms, including renin angiotensin system and endoplasmic reticulum stress signaling that can be targeted by therapeutic agents. Many studies have identified reliable tests for establishing diagnosis and response assessment of ocular GVHD. Efficacy of systemic and topical treatment for ocular GVHD is summarized. It is important for all health professionals taking care of HCT recipients to have adequate knowledge of ocular GVHD for optimal care.
Date Issued
2019-05
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Author(s)
Inamoto, Yoshihiro
Valdés-Sanz, Nuria
Ogawa, Yoko
Alves, Monica
Berchicci, Luigi
Galvin, John
Greinix, Hildegard
Hale, Gregory A
Horn, Biljana
Kelly, Debra
Liu, Hien
Rowley, Scott
Schoemans, Helene
Shah, Ami
Lupo Stanghellini, Maria Teresa
Agrawal, Vaibhav
Ahmed, Ibrahim
Ali, Asim
Bhatt, Neel
Byrne, Michael
Chhabra, Saurabh
DeFilipp, Zack
Fahnehjelm, Kristina
Farhadfar, Nosha
Horn, Erich
Lee, Catherine
Nathan, Sunita
Penack, Olaf
Prasad, Pinki
Rotz, Seth
Rovó, Alicia  
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Yared, Jean
Pavletic, Steven
Basak, Grzegorz W
Battiwalla, Minoo
Duarte, Rafael
Savani, Bipin N
Flowers, Mary E D
Shaw, Bronwen E
Petriček, Igor
Additional Credits
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Journal
Bone marrow transplantation
Publisher
Nature Publishing Group
ISSN
0268-3369
Access(Rights)
restricted
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify